Next Article in Journal
Nanotechnology-Based Medical Devices for the Treatment of Chronic Skin Lesions: From Research to the Clinic
Previous Article in Journal
Development of a Thymoquinone Polymeric Anticancer Nanomedicine through Optimization of Polymer Molecular Weight and Nanoparticle Architecture
Previous Article in Special Issue
Nanoparticle-Mediated Therapeutic Application for Modulation of Lysosomal Ion Channels and Functions
Open AccessReview

Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting

1
Center for Hematology and Regenerative Medicine (HERM), Department of Medicine, Karolinska Institute, 14183 Stockholm, Sweden
2
Animal Health Research Centre (CISA)-INIA, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, 28130 Madrid, Spain
3
Department of Immunology and Oncology, and NanoBiomedicine Initiative, Centro Nacional de Biotecnología (CNB)-CSIC, 28049 Madrid, Spain
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(9), 812; https://doi.org/10.3390/pharmaceutics12090812
Received: 23 July 2020 / Revised: 19 August 2020 / Accepted: 24 August 2020 / Published: 27 August 2020
(This article belongs to the Special Issue Inorganic Nanoparticles for Cancer Immunotherapy and Diagnosis)
Adoptive cell transfer therapy is a promising anti-tumor immunotherapy in which effector immune cells are transferred to patients to treat tumors. However, one of its main limitations is the inefficient trafficking of inoculated effector cells to the tumor site and the small percentage of effector cells that remain activated when reaching the tumor. Multiple strategies have been attempted to improve the entry of effector cells into the tumor environment, often based on tumor types. It would be, however, interesting to develop a more general approach, to improve and facilitate the migration of specific activated effector lymphoid cells to any tumor type. We and others have recently demonstrated the potential for adoptive cell transfer therapy of the combined use of magnetic nanoparticle-loaded lymphoid effector cells together with the application of an external magnetic field to promote the accumulation and retention of lymphoid cells in specific body locations. The aim of this review is to summarize and highlight the recent findings in the field of magnetic accumulation and retention of effector cells in tumors after adoptive transfer, and to discuss the possibility of using this approach for tumor targeting with chimeric antigen receptor (CAR) T-cells. View Full-Text
Keywords: magnetic targeting; cancer immunotherapy; adoptive cell transfer therapy; chimeric antigen receptor (CAR) T-cells magnetic targeting; cancer immunotherapy; adoptive cell transfer therapy; chimeric antigen receptor (CAR) T-cells
Show Figures

Figure 1

MDPI and ACS Style

Sanz-Ortega, L.; Rojas, J.M.; Barber, D.F. Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting. Pharmaceutics 2020, 12, 812. https://doi.org/10.3390/pharmaceutics12090812

AMA Style

Sanz-Ortega L, Rojas JM, Barber DF. Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting. Pharmaceutics. 2020; 12(9):812. https://doi.org/10.3390/pharmaceutics12090812

Chicago/Turabian Style

Sanz-Ortega, Laura; Rojas, José M.; Barber, Domingo F. 2020. "Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting" Pharmaceutics 12, no. 9: 812. https://doi.org/10.3390/pharmaceutics12090812

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop